CD79A and COVID-19: Longitudinal studies of antibody responses after COVID-19 have revealed increased IgM, IgA, and IgG levels in the serum or plasma against S and the nucleocapsid protein (N) of SARS-CoV-2 after disease onset (13, –, 20).